Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Top 10 Trends to Watch in Ophthalmology
The field of ophthalmology is constantly evolving with new technologies and treatments emerging every year. In the next decade, we can expect even more advancements that will revolutionize the way we approach eye care. Here are the top 10 eye…
Japanese Astellas Pharma Acquires Iveric Bio for $5.9 Billion
Astellas Pharma, a Japanese drugmaker, announced the acquisition of Iveric Bio, a pharmaceutical company that is currently in the late stages of developing a geographic atrophy drug. The acquisition is valued at $5.9 billion, and under the terms of the…
Ophthalmology’s Leap with Emerging Technologies
In a recent survey conducted on LinkedIn by the Ophthalmology Breaking News (OBN), ophthalmology professionals were asked to identify the emerging technology they believed held the most promise for improving surgical outcomes in their field. The results shed light on…
New FDA Warning: Hearing Impairment Risks in TEPEZZA
The US Food and Drug Administration (FDA) has taken action to update the warning label on Horizon Pharmaceutical’s TEPEZZA, a drug used to treat thyroid eye disease (TED), to include the risk of hearing impairment or loss. The recent addition…
Edenlux’s Otus Personal EYE-Trainer | OBN
The Otus personal eye-trainer, developed by Edenlux, has launched a campaign through Indiegogo. The device uses training called Vision Therapy to relieve the stress of the eyes. Vision Therapy is an exercise that repeats the contraction and relaxation of the…
FDA Approves Vuity for Twice-Daily Dosing in Presbyopia
AbbVie, the parent company of Allergan, has announced that the FDA has granted approval for the use of Vuity (pilocarpine HCl ophthalmic solution) 1.25% twice a day in adults suffering from presbyopia. The second dose, consisting of an additional drop…
FDA Accepts Application for Genentech’s Vabysmo for RVO
Genentech announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The sBLA is based on data from the phase 3 BALATON and…
Norlase Raises $11M in Funding for ECHO Pattern Laser
Norlase, a leading laser technology company, has recently secured its largest investment round to date, raising $11 million. This significant funding will empower Norlase to expedite the production ramp-up of its cutting-edge ECHO pattern laser, which recently received FDA clearance…
Stuart Therapeutics and Glaukos’ Exclusive License Deal
Stuart Therapeutics announced that it has signed an exclusive agreement with Glaukos Corporation. In this agreement, Glaukos gains exclusive global rights to develop and market Stuart’s proprietary drug candidate, ST-113, which focuses on neuroprotection in the context of glaucoma. ST-113,…
Alimera Wraps Synchronicity Study Enrollment for Yutiq in Uveitis
Alimera Sciences has reached its enrollment target for the Synchronicity study, marking a significant milestone in the prospective, open-label clinical investigation of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg). The study focuses on assessing the safety and efficacy of Yutiq in…